CClinicalTrials.gg
CompletedNCT05461950INTACTUpdated Jun 4, 2024

Intact-cord Stabilisation and Physiology-based Cord Clamping in Caesarean Sections

An observational study in Cesarean Section and Infant Conditions, sponsored by Helse Møre og Romsdal HF. Completed at 1 site in Norway. Open to female participants aged 32 Weeks to 42 Weeks. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Helse Møre og Romsdal HF · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
263
Ages
32 Weeks to 42 Weeks
Sex
Female
01

Study summary

This is a feasibility study with historical control designed to evaluate whether delivery of the placenta prior to umbilical cord clamping at caesarean sections is a feasible, safe and acceptable way of facilitating intact-cord stabilisation of preterm and term newborn infants.

Read the detailed description

Standard procedure when an infant is delivered by caesarean section is to wait to clamp the umbilical cord for approximately one minute, and then transfer the infant to a designated area for assessment and stabilisation. If the infant needs immediate resuscitation, the umbilical cord is cut earlier to expedite transfer to resuscitation equipment and qualified care (including stimulation, clearing airways and respiratory support).

It has been suggested in several pilot and clinical studies that keeping the umbilical cord intact during the infant's transition from intra- to extrauterine life may improve outcomes and survival, especially for preterm infants. Since length of the umbilical cord is limited, finding ways to avoid cutting the cord while initiating stabilisation and care is warranted. To date, most studies have reported on interventions that involve mobile resuscitation equipment; thus keeping the infant in close proximity to the mother. This may be extra challenging in caesareans sections, especially due to space constraints and maintenance of sterility.

The objective of this study to determine whether extra-uterine placental transfusion to facilitate intact-cord stabilisation and physiology-based cord clamping for infants delivered by caesarean section is feasible, safe and acceptable for infants and their mothers, as well as for involved personnel.

02

Conditions studied

  • Cesarean Section
  • Infant Conditions

Keywords

  • infant stabilisation
  • intact umbilical cord
  • umbilical cord clamping
  • placental transfusion
  • cesarean section
03

In context

Lead sponsor

Helse Møre og Romsdal HF is the lead sponsor of 24 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
32 Weeks to 42 Weeks
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women planning to give birth at Clinic Ålesund are candidates for enrolment in this clinical study. Pregnant women will be invited to participate when called for second trimester routine ultrasound scan. They will be asked for preliminary consent in the event of intrapartum or planned cesarean section and fullfilment of inclusion cirteria. Women having ultrasound scans done elsewhere, who are later referred to Clinic Ålesund, may be invited to participate after admission, but will not be approached for consent if delivery is imminent. Both parents (if applicable) must consent on behalf of their infant

Inclusion criteria

  • live infants (singletons or dichorionic twins) born in gestational week 32+0 to 42+0
  • delivered by CS in regional anaesthesia
  • immediate care may be planned with involved personnel prior to delivery
  • informed maternal consent is obtained (parental consent on behalf of the unborn child).

Exclusion criteria

Exclusion Criteria:

  • twins, triplets
  • significant congenital malformations
  • placenta complications with high risk of abnormal maternal blood loss
  • severe fetal distress requiring cesarean section in general anaesthesia (crash CS)
  • participation in any other clinical study within the last month
  • not sufficient time for preparations or collection of maternal/parental consent
  • mother does not comprehend Norwegian or English
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
263 participants (actual)
Patient registry
No

Groups and cohorts

  • Self-breathing infants

    Vigorous infants with spontaneous onset of respiration within one minute after delivery by cesarean section, receiving extra-uterine placental transfusion and physiology-based cord clamping

    Procedure: Extrauterine placental transfusion and physiology-based umbilical cord clamping

  • Infants with respiratory support

    Infants with no or poor spontaneous onset of respiration after delivery by cesarean section, receiving extra-uterine placental transfusion, intact-cord stabilisation (any respiratory support) and physiology-based cord clamping after transfer to resuscitation table

    Procedure: Extrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping

  • Historical control group

    Infants delivered by cesarean section in a time period when delayed cord clamping after 1-3 minutes was default procedure. Less-than-vigorous infants needing respiratory support or full resuscitation had their umbilical cords cut early (within 30 seconds)

    Procedure: Delayed umbilical cord clamping

Interventions

  • ProcedureExtrauterine placental transfusion and physiology-based umbilical cord clamping

    Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room, the umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infants is breathing regularly (within 10 minutes after delivery)

  • ProcedureExtrauterine placental transfusion, intact cord stabilisation and physiology-based umbilical cord clamping

    Placenta is delivered prior to umbilical cord clamping to facilitate placental transfusion. Infant and placenta are transferred to a warmer in an adjacent room and necessary respiratory support is initiated (CPAP or PPV) by a neonatal team. The umbilical cord is clamped and cut when the cord is white, pulsations have ceased and the infant is breathing regularly with or without support (at maximum 10 minutes after delivery)

  • ProcedureDelayed umbilical cord clamping

    Umbilical cord is clamped and cut minimum 60 seconds after delivery to facilitate placental transfusion. Placenta is delivered after cord clamping. Infants needing respiratory support or other stabilisation are transferred to a warmer in the adjacent room where a neonatal team is waiting.

06

What researchers measure

Primary outcomes

  1. Intervention fidelity (cohort 1)

    Extra-uterine placental transfusion + physiology-based cord clamping applied (for vigorous infants), measured as proportion of completed checklists. Registered by staff, using checklists in the operating room.

    Time frame: First 10 minutes after delivery

  2. Intervention fidelity (cohort 2)

    Extra-uterine placental transfusion + intact-cord stabilisation + physiology-based cord clamping applied (for infants needing any respiratory support), measured as proportion of completed checklists. Registered by staff, using checklists in the operating room.

    Time frame: First 10 minutes after delivery

Secondary outcomes

  1. Dry-electrode ECG attached (cohort 1+2)

    Time from birth to dry-electrode ECG (NeoBeat) is attached to the infant's chest or abdomen (measured in seconds). Registered on a checklist by a time-keeper in the operating room.

    Time frame: Within 10 seconds after birth

  2. First cry or breathing effort (cohort 1+2)

    Time from birth to infant's first cry or attempt of spontaneous breathing (measured in minutes and seconds). Assessed by attending midwife or pediatric registrar. Registered on a checklist by a time-keeper in the operating room.

    Time frame: Within 10 minutes after birth

  3. Heart rate (cohort 1+2)

    Infant's heart rate after birth measured by a dry-electrode ECG (NeoBeat). Registered on a special data collection sheet by a timekeeper or attending midwife. Data are transferred wirelessly from the NeoBeat device to the Liveborn App (installed on a designated tablet) for storage and further analysis.

    Time frame: First 10 -15 minutes after birth

  4. Umbilical cord blood samples (cohort 1+2)

    Time from birth to sampling for umbilical cord blood gas analysis (arterial and venous) completed (measured in seconds). Registered on a checklist by a time-keeper in the operating room.

    Time frame: Within 40-60 seconds after birth

  5. Apgar score (cohort 1+2)

    Composite of heart rate, breathing effort, skin colour, muscle tone and reflexes (each sub scale 0 (absent), 1, 2 (normal). Minimum 0, maximum 10. Assessed by the attending midwife or pediatric registrar, registered on a special data collection sheet by a timekeeper in the operating room

    Time frame: At 1 minute after birth

  6. Delivery of placenta (cohort 1+2)

    Time from birth to delivery of the placenta (measured in minutes ans seconds), registered on checklist by a time-keeper in the operating room

    Time frame: At 1 minute (+/- 10 seconds) after birth

  7. Respiratory support (cohort 2)

    Type of respiratory support applied. Alternatives are: CPAP (Continuous Positive Airway Pressure) or PPV (Positive Pressure Ventilation) Registered on a special data collection sheet by the attending neonatal team or midwife

    Time frame: First 10-15 minutes after birth

  8. Duration of respiratory support (cohort 2)

    Duration of respiratory support (CPAP or PPV), measured in minutes and seconds. Registered on a special data collection sheet by the attending neonatal team or midwife

    Time frame: First 10-15 minutes after birth

  9. Apgar score

    Composite of heart rate, breathing effort, skin colour, muscle tone and reflexes (each sub scale 0 (absent), 1, 2 (normal). Minimum 0, maximum 10. Assessed and registered on a special data collection sheet by the attending midwife or neonatal nurse

    Time frame: At 5 minutes after birth (cohort 1+2)

  10. Stabilisation (cohort 2)

    Time from birth to stabilisation achieved (regular breathing, heartrate (HR) \>100, Saturation (SpO2) \>85%, inspired oxygen fraction (FiO2) \<40%. Measured in minutes and seconds. Assessed and registered on a special data collection sheet by the attending midwife or neonatal nurse

    Time frame: Within 10-20 minutes after birth

  11. Cord clamping time (cohort 1+2)

    Time from birth to umbilical cord clamping (measured in minutes and seconds), registered on a special data collection sheet by the attending midwife

    Time frame: Within 10 minutes after birth

  12. Apgar score (cohort 1+2)

    Composite of heart rate, breathing effort, skin colour, muscle tone and reflexes (each sub scale 0 (absent), 1, 2 (normal). Minimum 0, maximum 10. Assessed and registered on a special data collection sheet by the attending midwife or neonatal nurse

    Time frame: At 10 minutes after birth

  13. Skin-to-skin-contact (cohort 1+2)

    Time from birth to continuous skin-to-skin contact between infant and mother (or other parent), measured in minutes. Registered on a checklist by the attending midwife or neonatal nurse

    Time frame: Within 2 hours after birth

  14. Residual placenta volume (cohort 1+2)

    Drained and weighed residual blood volume from placenta and umbilical cord after cord clamping (measured in grams, converted to milliliters by a ratio of 1.05:1). Registered by the attending midwife or assistant nurse

    Time frame: Within 10-15 minutes after birth

Other outcomes

  1. Post-cesarean infection (all cohorts)

    Prevalence of maternal post-operative wound infection needing antibiotic therapy. Registered in a dedicated paper form in the patient's record by the attending obstetrician

    Time frame: Within14 days after surgery (cesarean section)

  2. Abnormal blood loss (all cohorts)

    Prevalence of abnormal maternal blood-loss during surgery and wound closure (more than 1000 ml). Estimated by staff by visual inspection and count of blood-soaked compresses. Registered in the patient's record by the attending obstetrician

    Time frame: 45 minutes from incision time

  3. Pre-operative maternal Hemoglobin

    Maternal Hemoglobin value from a venous blood sample taken before cesarean section, measured in grams per 100 ml. Registered on a checklist and in the patient's record by the midwife

    Time frame: Within 48 hours before cesarean section

  4. Post-operative maternal Hemoglobin

    Maternal Hemoglobin value from a venous blood sample taken after cesarean section, measured in grams per 100 ml. Registered on a checklist and in the patient's record by the midwife

    Time frame: Within 24 hours after cesarean section

  5. Low Apgar score (all cohorts)

    Prevalence of infant Apgar score less than 7 (mild asphyxia), composite of heart rate, breathing effort, skin colour, muscle tone and reflexes (subscale range from 0-2). Assessed and registered on a special data collection sheet and in the patient's record by the attending midwife or neonatal team

    Time frame: At 5 minutes after birth

  6. Infant hypothermia (all cohorts)

    Prevalence of infant rectal temperature less than 36.5 degrees celsius, measured by a thermometer and registered on a special data collection form and in the patient's record by the attending midwife or neonatal team

    Time frame: Within 2 hours after birth

  7. Admittance to Neonatal Intensive Care Unit (NICU) (all cohorts)

    Indication for infant's admittance to neonatal intensive care unit after birth. Assessed by the attending pediatric registrar or neonatologist. Registered in a special data collection sheet and in the patient's record

    Time frame: Within 24 hours after birth

  8. Days in NICU (all cohorts)

    Infant's length of stay i neonatal intensive care unit, measured in days. Registered on a checklist and in the patient's record by the neonatal team

    Time frame: Maximum 2 months

07

Study locations

1 site
  • Møre and Romsdal Hospital Trust
    Ålesund, Møre And Romsdal 6026, Norway
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05461950
Lead sponsor
Helse Møre og Romsdal HF
Collaborators
Norwegian University of Science and Technology
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Oct 3, 2022
Primary completion
Mar 31, 2024
Completion
Mar 31, 2024
Last update
Jun 4, 2024

Study contacts

Beate H Eriksen, MD/PhD
principal investigator · Møre and Romsdal Hosptal Trust / Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion